Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

First International Summit on Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, of Emory University, discusses the ways in which clinical pharmacology can help yield cost savings without sacrificing efficacy by, for example, altering regimens to extend drug supplies, lowering doses, dosing less frequently, or shortening the duration of treatment.

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Mar

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

David A. Hyman, MD, JD, on Inclusive Shared Savings

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Cutting Cancer Care Costs With Alternative Pharmacologic Options

Daniel Goldstein, MD: Interventional Pharmacoeconomics - Why and How

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Fifteen-Year Results From SWOG S0016 Suggest Follicular Lymphoma May Be Curable

Can ctDNA Negativity Predict Metastasis-Free Survival in Muscle-Invasive Bladder Cancer

AI Model May Predict Cancer Risk in Patients With Colitis-Associated Low-Grade Dysplasia

Addition of Hormone Therapy to Postoperative Radiotherapy in Prostate Cancer

Advanced RCC After Immunotherapy Belzutifan Plus Lenvatinib or Cabozantinib